On the other hand, modifying AhR and CYP1A1/2 expression/activity in particular pathological states may be a useful strategy in the therapy of chronic kidney disease and cardiovascular diseases evoked by toxic tryptophan indole metabolites. The gene discussed is CYP1A1; the disease is chronic kidney disease.